Answers are grounded in this paper and cite their sources.
and also known as lysine-specific demethylase 1 (LSD1) plays important roles in the development and function of the brain. Vafidemstat is a KDM1A inhibitor that has shown beneficial effects in preclinical and clinical trials for the treatment of neuropsychiatric disorders, including borderline personality disorder (BPD), autism spectrum disorder (ASD), and attention-deficit hyperactivity disorder (ADHD). This article reviews available preclinical and clinical data on the use of vafidemstat in the treatment of these disorders. Vafidemstat appears to be a potential new and safe drug for the treatment of these disorders.
No takes yet. Share an insight, caveat, or question.
Peedicayil et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: